Other Events ·
City Therapeutics doses first participant in Phase 1 trial of CITY-RBP4 for Stargardt disease
CTYCity Therapeutics, Inc.
City Therapeutics announced the dosing of the first participant in a Phase 1 clinical trial for CITY-RBP4, an investigational RNAi therapeutic candidate designed to treat Stargardt disease type 1. The multicenter study evaluates safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple subcutaneous doses. Initial data from the trial is expected in mid-2027. City Therapeutics operates as a clinical-stage biotechnology company engineering RNA interference therapeutics.